“We now have preliminary evidence demonstrating that the Brain-Pacer-driven positive neural activity changes are real.”


Irvine, Calif. — Niraxx Light Therapeutics, a leader in wearable neurotechnology, today announced positive initial results from its Niraxx Brain Pacer Efficacy Study. Early findings show that functional connectivity is significantly increased with a single 40-minute “Find Focus” session. Enhanced neural connectivity means stronger information processing among brain regions, and is expected to result in better concentration and attention.

The Brain Pacer is the NeuroTech company’s first e-textile wearable solution. The Bluetooth-controlled device provides on-demand non-medication light therapy in six tailored programs. The application of unique wavelengths of near-infrared light activates the brain’s natural restorative and regenerative processes, resulting in enhanced brainpower and wellbeing.

The study measured brain activity with electrodes placed on the scalp, known as electroencephalography (EEG). By capturing the EEG from subjects both before and after the application of the Brain Pacer, it was shown that the connectivity between different regions in the brain is increased after the session. “We are also finding that subjects report significant increases in levels of energy and alertness,” said Jacek Dmochowski, PhD, Chief Technology Officer. He is an Assistant Professor in the Department of Biomedical Engineering at the City College of New York (CUNY). His research focuses on exploring novel non-invasive techniques for sensing and modulating brain activity and applying machine learning to develop better interventions for the brain. He is the Principal Investigator of the Brain Pacer controlled study.

Dmochowski has also started a controlled study comparing active (working) and sham (not working) Brain Pacers. The study is currently enrolling additional subjects and is expected to scale up this year. “This is really exciting because we now have preliminary evidence demonstrating that the Brain-Pacer-driven positive neural activity changes are real and not derived from users’ anticipation of Brain-Pacer effects,” he said.

Niraxx licenses its PBM technology from Massachusetts General Hospital (MGH), a teaching hospital for Harvard University. The hospital’s psychiatry department has been ranked No. 1 in the U.S. for 16 consecutive years by U.S. News & World Report. MGH is also home to the Wellman Center for Photomedicine, the largest academic research center in the world dedicated to studying the clinical application of light.

About Niraxx Light Therapeutics
Niraxx is a NeuroTech company that aims to democratize access to safe, effective brain health care by delivering truly wearable, personalized solutions integrating PBM and digital technologies in clothing. Our mission is to empower individuals to take charge of their brain health for life. Recharge your mind, recharge life! For more information, visit https://niraxx.com.

Media Contact
Sherry Hsieh
Director of Marketing
sherry.hsieh@niraxx.com